ArticleScientific reports2026
Fructooligosaccharide supplementation ameliorates gut associated metabolic dysregulation in estrogen-deprived rats via targeting oxidative stress, inflammation, apoptosis, and gut microbiome.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Estrogen is a key regulatory hormone that maintains metabolic and gut homeostasis by modulating immune responses, microbial composition, and energy balance. However, estrogen deficiency is strongly associated with gut associated metabolic dysregulation (GAMD), characterised by increased oxidative stress, systemic inflammation, and altered gut microbiome (GM). Prebiotic compounds such as fructooligosaccharide (FOS) have shown potential in modulating gut and metabolic health. This study aimed to assess the therapeutic potential of FOS supplementation in restoring GAMD in estrogen-deprived rats. To induce GAMD, female Sprague-Dawley rats were bilaterally ovariectomized (OVX) and fed FOS for 28 days to restore the gut and associated metabolic functions. At the end, various physiological, anthropometric, and adiposity markers were assessed. Further, oxidative stress, inflammation, apoptosis, and histopathological parameters were evaluated in the colon and liver. Furthermore, gut mucosa, tight junction gene (TJG), and GM were also analysed. OVX rats fed FOS (50 & 100 mg/kg) for 28 days showed recovery of basic physiological, anthropometric, and adiposity markers. There was also a substantial reduction in apoptosis, inflammation, and oxidative stress in both the colon & liver. Additionally, gut mucosa, TJG, and GM were restored. Histopathological examinations revealed improved gut integrity (mucosal layer & goblet cells) and liver health (healthy hepatocytes). FOS ameliorates the postmenopausal GAMD by targeting oxidative stress, inflammation, and GM. Therefore, FOS may be a promising candidate for preventing postmenopausal complications in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.